Actively Recruiting
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Led by Neurocrine Biosciences · Updated on 2026-05-08
50
Participants Needed
21
Research Sites
70 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
CONDITIONS
Official Title
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder at least 3 months before screening
- Diagnosed with at least mild neuroleptic-induced tardive dyskinesia for at least 3 months before screening
You will not qualify if you...
- Presence of Parkinsonism or abnormal involuntary movements more prominent than tardive dyskinesia
- Diagnosis of moderate or severe substance use disorder within the last 6 months
- History of long QT syndrome, cardiac arrhythmia, or severe liver impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Neurocrine Clinical Site
Bryant, Arkansas, United States, 72022
Actively Recruiting
2
Neurocrine Clinical Site
Chino, California, United States, 91710
Actively Recruiting
3
Neurocrine Clinical Site
Fountain Valley, California, United States, 92708
Actively Recruiting
4
Neurocrine Clinical Site
Fresno, California, United States, 93720
Actively Recruiting
5
Neurocrine Clinical Site
Long Beach, California, United States, 90807
Actively Recruiting
6
Neurocrine Clinical Site
Orange, California, United States, 92866
Actively Recruiting
7
Neurocrine Clinical Site
Redlands, California, United States, 92373
Actively Recruiting
8
Neurocrine Clinical Site
San Diego, California, United States, 92123
Actively Recruiting
9
Neurocrine Clinical Site
Bonita Springs, Florida, United States, 34134
Actively Recruiting
10
Neurocrine Clinical Site
Hialeah, Florida, United States, 33012
Actively Recruiting
11
Neurocrine Clinical Site
Miami, Florida, United States, 33144
Actively Recruiting
12
Neurocrine Clinical Site
Miami, Florida, United States, 33176
Actively Recruiting
13
Neurocrine Clinical Site
Orange City, Florida, United States, 32763
Actively Recruiting
14
Neurocrine Clinical Site
Port Charlotte, Florida, United States, 33980
Actively Recruiting
15
Neurocrine Clinical Site
Tampa, Florida, United States, 33629
Actively Recruiting
16
Neurocrine Clinical Site
Augusta, Georgia, United States, 30912
Actively Recruiting
17
Neurocrine Clinical Site
Marietta, Georgia, United States, 30060
Actively Recruiting
18
Neurocrine Clinical Site
Naperville, Illinois, United States, 60563
Actively Recruiting
19
Neurocrine Clinical Site
Omaha, Nebraska, United States, 68124
Actively Recruiting
20
Neurocrine Clinical Site
Independence, Ohio, United States, 44131
Actively Recruiting
21
Neurocrine Clinical Site
Richmond, Virginia, United States, 23226
Actively Recruiting
Research Team
N
Neurocrine Medical Information Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here